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Nutraceuticals for joint health and 
OA biomarkers
Osteoarthritis an «old disease»


























Act II: a dysregulation of chondrocyte
metabolism
IL-1b



























































ACT IV: a metabolic and systemic




















Bone driven   














OA treatments and 
limitations







Patient education, physical and
occupational Therapy, weight loss
Limitations
Costly, invasive procedure
Primarily indicated for «end stage » OA
GI bleeding or other complications
CV risks
Renalr complications





Drug discovery is protracted, risky and 
costly
Nothing new to offer at the 
patients and the OA research 
community
Clinical trials end-point




 Structure modification (1 to 3 years)
Imaging outcomes
Joint Space Narrowing
The Gold Standard 
(Radiography) is inadequate
…We need better methods to predict OA 
progression and response to therapy 















Soluble or « wet » biomarkers « Dry » biomarkers
A biomarker is a characteristic that is objectively
measured and evaluated as an indicator of 
normal biologic processes, pathogenic
processes, or pharmacologic responses to a 
therapeutic intervention. » 
Biomarkers Definitions Working Group I. Biomarkers and surrogate endpoints: 




28 identified biochemical makers1



















Coll2-1 and Coll2-1NO2: 










 Specific of degradated cartilage





 65 male HA guinea pigs
 2/3 w old + 1w acclimatation
– 5 « Baseline », sacrified at T0 (group E)
– 15 group A Oleuropein
– 15 group B (control)
– 15 group C Rutin











Each week : weighing
W35
W7/8                           W19/20                          W30          W35










































*         *                     **






D = Rutin + Curcumin










































Biomarkers in serum : Coll2-1NO2
*                          *      *
*     **        *       **          *































« Proof-of-concept study »
-22 knee OA patients
-2x3 caps (42 mg BOC)/days
-3 months treatment
Henrotin Y, Priem F, Mobasheri A, Springerplus, 2013
Criteria of efficacy









– Variation of pain on movement during the last 24H
– Variation of Global Patient Assessment on disease activity
TIFLEXY Study
A proof-of-concept study
Henrotin et al., BMC Complem Altern Med,2014
Baseline 84 days of treatment p-Value
sColl2-1 (nmol/L) 302.21+/-53 257.84 +/-52.78 0.002*
sColl2-1NO2 (nmol/L) 0.71 +/- 0.78 0.80 +/- 0.24 NS
sCTX-II (ng/L) 11.81 +/-7.98 13.17+/-4.96 NS
sFib3-1 (pmol/L) 707.05 +/- 178.79 765.20 +/- 261.90 NS
sFib3-2 (pmol/L) 580.58 +/- 103.59 636.74 +/- 119.73 NS
sCRP (mg/L) 10.42 +/- 30.27 3.10 +/- 2.40 NS
sMPO (ng/ml) 27.20 +/- 29.05 21.96 +/- 14.65 NS
Time (days)


























Coll-2-1 (nmol/L) between day 0 and day 84
%









FDA/OARSI Recommendation to advance the 
science of biomarkers
 The co-development (Drug + biomarker) 
pathway should be determined early in 
development.
 Used biomarkers in combination rather than
individually
 Used in combination with imaging (MRI)
 Biomarkers may serves as titration tools; 
falicitating dose setting in early clinical study
 Appropriate analytical validation of 
immunoassay
Thank you for your attention !
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Flexofytol 2 X 3 caps/days during 3 months
